The observation on the effect of medroxyprogesterone acetate tablets combined with oxaliplatin and paclitaxel in the treatment of advanced endometrial cancer / 中国医师进修杂志

ABSTRACT

Objective:To explore the clinical effect of medroxyprogesterone acetate tablets combined with oxaliplatin and paclitaxel in the treatment of advanced endometrial cancer.Methods:Ninety-two patients with advanced endometrial cancer admitted to Qihe People′s Hospital of Shandong Province from January 2014 to May 2019 were selected. According to the entry number, they were divided into the observation group (the last number was odd, receiving medroxyprogesterone acetate tablets + oxaliplatin + paclitaxel treatment) and the control group (the last number was even, receiving oxaliplatin + paclitaxel treatment). The efficacy and safety of the two groups were evaluated, and the changes of serum human carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF), human epididymal protein (HE4) and immune function, physical status and quality of life before and after the treatment were compared and analyzed.Results:The total efficacy in the observation group was higher than that in the control group 78.26%(36/46) vs. 58.70%(27/46), the difference was statistically significant ( P<0.05). After treatment, the levels of serum CA125, VEGF, HE4 in the observation group were lower than those in the control group (23.27 ± 5.65) kU/L vs. (30.55 ± 5.71) kU/L, (214.94 ± 23.89) ng/L vs. (247.62 ± 19.97) ng/L, (26.62 ± 4.23) pmol/L vs. (32.24 ± 6.68) pmol/L, the differences were statistically significant ( P<0.05). After treatment, the levels of serum natural killer cells (NK), helper T lymphoid cells (Th), cytotoxic T lymphoid cells (Tc) in the observation group were higher than those in the control group (0.287 ± 0.032 vs. 0.239 ± 0.027, 0.403 ± 0.052 vs. 0.333 ± 0.046, 0.261 ± 0.029 vs. 0.228 ± 0.026, the differences were statistically significant ( P<0.05). After treatment, the score of Eastern Cooperative Oncology Group (ECOG) in the observation group were lower than that in the control group (1.37 ± 0.26) scores vs. (1.89 ± 0.34) scores; the score of Quality of Life Questionnaire(QLQ-C30) in the observation group was higher than that in the control group (65.69 ± 7.58) scores vs. (58.35 ± 6.26) scores, the differences were statistically significant ( P<0.05). The incidence of adverse reactions between the two groups had no significant difference ( P>0.05). Conclusions:Medroxyprogesterone acetate tablets combined with oxaliplatin and paclitaxel is safe and effective in the treatment of advanced endometrial cancer. This method can reduce the concentration of tumor markers in patients, inhibit tumor angiogenesis, and improve immune function, physical fitness and quality of life.